Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law. The suit, filed in a Delaware court, is sealed, according to Bloomberg, but in a separate court document, Sage noted ...

Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their shared vision to help women suffering from PPD.

Jan 21, 2025 · Sage said it's board is reviewing Biogen's buyout offer, but a Mizuho analyst said a deal seems unlikely at the current price.

Jan 27, 2025 · Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best ...

Jan 28, 2025 · Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the company.

3 days ago · Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.

Jan 10, 2025 · No Shareholder Action Required at This Time CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 10, 2025-- Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share ...

Jan 27, 2025 · Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to “maximize” shareholder value.

Sep 26, 2024 · (RTTNews) - Sage Therapeutics, Inc. (Sage) announced Thursday that Biogen Inc. (BIIB) has terminated its rights under the collaboration and license agreement specific to the SAGE-324...

Jan 28, 2025 · Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.